Loading
A phase 1 trial of IMNN-001 run by Imunon, completed.
Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian Cancer is a phase 1 interventional study registered as NCT02480374 by Imunon, with 18 participants enrolled, started 2015-09. Conditions recorded: Epithelial Ovarian Cancer, Fallopian Tube Cancer and Primary Peritoneal Cancer. Interventions recorded: IMNN-001.
Shares Imunon and the tag pipeline.
Shares IMNN-001, Imunon, Ovarian cancer.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/